iLite RANKL Assay Ready Cells

iLite RANKL Assay Ready Cells

$1,555.00

The iLite® RANKL Assay Ready Cells can be used for the quantification of RANKL activity, RANKL inhibitor activity or immunogenicity studies and determination of neutralizing antibody response against RANKL inhibitors in test samples, including human serum. The Eagle Biosciences iLite® RANKL Assay Ready Cells are for research use only.

SKU: BM4052 Categories: ,

iLite RANKL Assay Ready Cells

iLite RANKL Assay Ready Cells are Developed and Manufactured by Svar Life Science

The Eagle Biosciences iLite RANKL Assay Ready Cells are intended for:

  • Quantification of RANKL inhibitor activity
  • Quantification of functional RANKL
  • Determination of neutralizing antibodies against RANKL inhibitors

Content: 250 µL of Assay Ready Cells suspended in cryoprotective medium from Gibco
Receipt and Storage: Upon receipt confirm that adequate dry-ice is present, and the cells are frozen. Immediately transfer to -80°C storage. Cells should be stored at -80°C (do not store at any other temperature) and are stable as supplied until the expiry date shown. Cells should be used within 30 min of thawing and should be diluted immediately after thawing.
For Research Use Only

Key benefits of iLite Assays

  • Highly specific reporter gene cell lines
  • Very sensitive cell line responses (10 fold inductions)
  • Assay Ready Cells – ready-to-use from the freezer, without culturing of cells
  • Assays within a workday (typically 4-7 hour assays)
  • Normalization gene, which eliminates unwanted matrix effects

Product Description

iLite RANKL Assay Ready Cells are human HEK293 cells (ATCC# CRL-1573) which have been genetically engineered and optimized to be responsive to human soluble RANK Ligand (RANKL), resulting in a proportional expression of Firefly Luciferase. Normalization of cell counts, and serum matrix effects is obtained by a second reporter gene, a Renilla Luciferase reporter gene construct, under control of a constitutive promotor.

[1] The HEK-293 cell line has been used under a license obtained from AdVec Inc.

Related Products

Free soluble RANKL (sRANKL) ELISA Assay Kit

Additional Information

Background

Receptor activator of nuclear factor kappa-Β ligand (RANKL) is a cytokine of the tumor necrosis factor (TNF) superfamily and is expressed in many kinds of tissue, including bone, lung, lymph nodes and mammary glands. It exists in two forms, as a transmembrane protein or in a soluble form, and binds to the receptor activator of nuclear factor kappa B (RANK) which is mainly found at osteoclasts and immune cells.

Osteoprotegerin (OPG), is a soluble decoy factor regulating the RANKL-RANK interaction by binding RANKL and thereby decreasing the binding to RANK. (1) The RANK/RANKL/OPG cytokine system was discovered in the 1990s and identified for its key role in the bone metabolism through regulation of osteoclastogenesis. Besides bone remodeling, this cytokine system has been shown to play important roles in adaptive immunity, mammary gland development, thermoregulation of the central nervous system as well as tumor cell development and migration. (2)

Primary tumors, in breast and prostate cancers for example, commonly metastasize into the bone. Many cancers utilize the RANKL/RANK/OPG system to promote migration and implantation of cancer cells in the bone and support downregulation of the body’s tumor immune surveillance mechanism. (2,3) Denosumab (trade names Prolia and Xgeva), approved by the FDA in 2010, is a fully human monoclonal antibody to RANKL. It decreases bone turnover markers by blocking the RANKL/RANK pathway. The first approved indication for denosumab was osteoporosis and treatment-induced bone loss. Further clinical studies have led to the approval of denosumab for the prevention of skeletal-related events from bone metastases in cancer. RANKL inhibition is also being investigated for use in combination with other cancer immunotherapies to improve the effect of immune-checkpoint inhibitors targeting CTLA-4, PD-1, or PD-L1. (4,5)

Discover the Benefits of iLite®

 

Package Inserts

Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Product Citations